CD5 and neoplasm: ,21 The data from a phase I clinical trial (ClinicalTrials.gov: NCT03081910) conducted by Baylor College of Medicine demonstrated that CAR-T cells incorporated a murine-derived single-chain variable fragment (scFv) H65 targeting CD5 were safe and had anti-tumor activity in patients with r/r T cell malignancies.9